Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending February 15, 2018. The report discloses a transaction involving the grant of conditional share awards to a Person Discharging Managerial Responsibilities (PDMR) under the company's 2017 Performance Share Plan (PSP).
Key Financial Metrics
The filing does not report consolidated revenue, profit, cash flow, margins, debt, or liquidity metrics for the company. It focuses exclusively on executive compensation details.
- Transaction Date: February 14, 2018
- Instrument: Ordinary Shares of 25 pence each (ISIN: GB0009252882)
- Volume Granted: 366,704 shares
- Reference Price: £12.91 per share
- Recipient: Mr. L. Miels, President, Global Pharmaceuticals
Material Changes
No material changes to the company's financial position or operations are reported in this filing. The document serves as a regulatory notification of a specific equity award granted to a senior executive who joined the company in 2017.
Guidance, Outlook, and Performance Measures
The filing details the performance conditions attached to the 2017 PSP awards, which cover the three-year period from January 1, 2017, to December 31, 2019. Vesting is equally weighted across three measures:
- Total Shareholder Return (TSR) (1/3): Compared against a comparator group of nine other global pharmaceutical companies (including AstraZeneca, Pfizer, and Johnson & Johnson). Vesting begins at 44% if GSK ranks 5th (above median) and reaches 100% if ranked 1st through 3rd.
- Adjusted Free Cash Flow (AFCF) (1/3): Targets range from a threshold of £11.47 billion (25% vesting) to a maximum of £13.59 billion (100% vesting). Adjustments include legal settlements, pension contributions, and foreign exchange.
- R&D New Product Performance (1/3): Specific targets are not disclosed due to commercial sensitivity. Vesting ranges from 25% at the threshold to 100% for performance exceeding 122% of the target.
Dividends will accrue on the conditional awards but will only vest if the underlying awards vest at the end of the performance period.
Investor Verification Checklist
- Verify the specific vesting schedule and performance thresholds for the 2017 PSP in the company's full Annual Report or Remuneration Report.
- Confirm the final TSR ranking of GSK against the specified comparator group at the end of the 2019 performance period.
- Review future filings for the disclosure of the specific R&D new product targets once the performance period concludes.
- Monitor subsequent filings for any amendments to the performance measures or the PDMR's status.